CLIA Kit for Platelet Factor 4 (PF4) Mus musculus (Mouse) Sandwich CLIA

CXCL4; SCYB4; Chemokine C-X-C-Motif Ligand 4; Oncostatin-A; Iroplact

Add to Cart Distributors
Overview
Properties
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • CLIA Kit for Platelet Factor 4 (PF4) Packages (Simulation)
  • CLIA Kit for Platelet Factor 4 (PF4) Packages (Simulation)
  • CLIA Kit for Platelet Factor 4 (PF4) Results demonstration
  • SCA172Mu.jpg Typical Standard Curve
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Platelet Factor 4 (PF4) and the recovery rates were calculated by comparing the measured value to the expected amount of Platelet Factor 4 (PF4) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 90-99 95
EDTA plasma(n=5) 98-105 102
heparin plasma(n=5) 85-102 97

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Platelet Factor 4 (PF4) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Platelet Factor 4 (PF4) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Platelet Factor 4 (PF4) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 83-102% 95-103% 83-97% 80-103%
EDTA plasma(n=5) 85-97% 87-103% 86-101% 84-103%
heparin plasma(n=5) 80-96% 90-99% 80-101% 90-103%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
Substrate A 1×10mL Substrate B 1×2mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 100µL Substrate Solution. Incubate 10 minutes at 37°C;
8. Read RLU value immediately.

CLIA Kit for Platelet Factor 4 (PF4)

Test principle

The microplate provided in this kit has been pre-coated with an antibody specific to Platelet Factor 4 (PF4). Standards or samples are then added to the appropriate microplate wells with a biotin-conjugated antibody specific to Platelet Factor 4 (PF4). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then the mixture of substrate A and B is added to generate glow light emission kinetics. Upon plate development, the intensity of the emitted light is proportional to the Platelet Factor 4 (PF4) level in the sample or standard.;

Citations

  • Propofol lowers serum PF4 level and partially corrects hypercoagulopathy in endotoxemic ratsPubMed: 20601223
  • Secretome of apoptotic peripheral blood cells (APOSEC) attenuates microvascular obstruction in a porcine closed chest reperfused acute myocardial infarction model: role of platelet aggregation and vasodilationPubMed: 22899170
  • Platelets Recognize Brain-Specific Glycolipid Structures, Respond to Neurovascular Damage and Promote NeuroinflammationPubMed: PMC3608633
  • Effect of splenectomy on platelet activation and decompression sickness outcome in a rat model of decompressionPubmed:25311322
  • A Phellinus baumii–based supplement containing Salvia miltiorrhiza Bunge improves atherothrombotic profiles through endothelial nitric oxide synthase and cyclooxygenase pathwaysin vitro and in vivoscience:S1756464616300676
  • Aspirin, but Not Tirofiban Displays Protective Effects in Endotoxin Induced Lung Injurypubmed:27583400
  • Evidence of the Role of R-Spondin 1 and Its Receptor Lgr4 in the Transmission of Mechanical Stimuli to Biological Signals for Bone Formation.pubmed:28272338
  • Feasibility of improving platelet‑rich plasma therapy by using chitosan with high platelet activation abilitypubmed:28450960
  • Aspirin pre-treatment modulates ozone-induced fetal growth restriction and alterations in uterine blood flow in ratsPubmed: 30528429
  • Short and long-term changes in platelet and inflammatory biomarkers after cryoballoon and radiofrequency ablationPubmed: 30857843
  • Evaluating the Platelet Activation Related to the Degradation of Biomaterials by Scheme of Molecular Markers
  • Newly Identified HNP‐F from Human Neutrophil Peptide 1 Promotes HemostasisPubmed: 30927490
  • Data for short and long-term prothrombotic biomarkers after cryoballoon and radiofrequency ablation
  • Evaluating Platelet Activation Related to the Degradation of Biomaterials Using Molecular MarkersPubmed: 32812629
  • The Inhibitory Effect of Protamine on Platelets is Attenuated by Heparin without Inducing Thrombocytopenia in RodentsPubmed: 31533230
  • Feasibility study of use of rabbit blood to evaluate platelet activation by medical devicesPubmed: 31838449
  • The C5a/C5a receptor 1 axis controls tissue neovascularization through CXCL4 release from platelets34099640
  • The effect of ChAdOx1 nCov-19 vaccine on arterial thrombosis development and platelet aggregation in female ratsPubmed:35183388

Recommend products